Alzheimer's disease (AD) is the most common form of dementia. The risk of AD increases with age. Although two of the main pathological features of AD, amyloid plaques and neurofibrillary tangles, were already recognized by Alois Alzheimer at the beginning of the 20th century, the pathogenesis of the disease remains unsettled. Therapeutic approaches targeting plaques or tangles have not yet resulted in satisfactory improvements in AD treatment. This may, in part, be due to early-onset and late-onset AD pathogenesis being underpinned by different mechanisms. Most animal models of AD are generated from gene mutations involved in early onset familial AD, accounting for only 1% of all cases, which may consequently complicate our understanding of AD mechanisms. In this article, the authors discuss the pathogenesis of AD according to the two main neuropathologies, including senescence-related mechanisms and possible treatments using stem cells, namely mesenchymal and neural stem cells.

Department of Neuroscience 2nd Faculty of Medicine Charles University 5 Uvalu 84 150 06 Prague 5 Czech Republic

Department of Neuroscience Institute of Experimental Medicine Academy of Sciences of the Czech Republic Videnska 1083 142 20 Prague 4 Czech Republic

Zobrazit více v PubMed

O’Brien C. Auguste D. and Alzheimer’s disease. Science. 1996;273:28. doi: 10.1126/science.273.5271.28. PubMed DOI

Gouras G.K., Almeida C.G., Takahashi R.H. Intraneuronal Aβ accumulation and origin of plaques in Alzheimer’s disease. Neurobiol. Aging. 2005;26:1235–1244. doi: 10.1016/j.neurobiolaging.2005.05.022. PubMed DOI

Goedert M. Oskar Fischer and the study of dementia. Brain. 2009;132:1102–1111. doi: 10.1093/brain/awn256. PubMed DOI PMC

Maurer K., Volk S., Gerbaldo H. Augaste D and Alzheimer’s disease. Lancet. 1997;349:1546–1549. doi: 10.1016/S0140-6736(96)10203-8. PubMed DOI

Graeber M.B., Kosel S., Egensperger R., Banati R.B., Muller U., Bise K., Hoff P., Moller H.J., Fujisawa K., Mehraein P. Rediscovery of the case described by Alois Alzheimer in 1911: Historical, histological and molecular genetic analysis. Neurogenetics. 1997;1:73–80. doi: 10.1007/s100480050011. PubMed DOI

Graeber M.B., Kosel S., Grasbon-Frodl E., Moller H.J., Mehraein P. Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics. 1998;1:223–228. doi: 10.1007/s100480050033. PubMed DOI

Muller U., Winter P., Graeber M.B. A presenilin 1 mutation in the first case of Alzheimer’s disease. Lancet Neurol. 2013;12:129–130. doi: 10.1016/S1474-4422(12)70307-1. PubMed DOI

Rupp C., Beyreuther K., Maurer K., Kins S. A presenilin 1 mutation in the first case of Alzheimer’s disease: Revised. Alzheimers Dement. 2014;10:869–872. doi: 10.1016/j.jalz.2014.06.005. PubMed DOI

Anand R., Gill K.D., Mahdi A.A. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology. 2014;76:27–50. doi: 10.1016/j.neuropharm.2013.07.004. PubMed DOI

Imtiaz B., Tolppanen A.M., Kivipelto M., Soininen H. Future direction in Alzheimer’s disease from risk factors to prevention. Biochem. Pharmacol. 2014;88:661–670. doi: 10.1016/j.bcp.2014.01.003. PubMed DOI

Cacquevel M., Aeschbach L., Houacine J., Fraering P.C. Alzheimer’s disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes. PLoS ONE. 2012;7:e35133. doi: 10.1371/journal.pone.0035133. PubMed DOI PMC

Bateman R.J., Aisen P.S., de Strooper B., Fox N.C., Lemere C.A., Ringman J.M., Salloway S., Sperling R.A., Windisch M., Xiong C. Autosonal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res. Ther. 2011;3:1. doi: 10.1186/alzrt59. PubMed DOI PMC

Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., et al. Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med. 1997;3:67–72. doi: 10.1038/nm0197-67. PubMed DOI

Selkoe D.J. Alzheimer’s disease: Genes, proteins, and therapy. Physiol. Rev. 2001;81:741–766. doi: 10.1101/cshperspect.a004457. PubMed DOI

Selfridge J.E., Lezi E., Lu J., Swerdlow R.H. Role of mitochondrial homeostasis and dynamics in Alzheimer’s disease. Neurobiol. Dis. 2013;51:3–12. doi: 10.1016/j.nbd.2011.12.057. PubMed DOI PMC

Mahley R.W., Nathan B.P., Pitas R.E. Apolipoprotein E. Structure, function, and possible roles in Alzheimer’s disease. Ann. N. Y. Acad. Sci. 1996;777:139–145. doi: 10.1111/j.1749-6632.1996.tb34412.x. PubMed DOI

Mahley R.W., Rall S.C., Jr. Apolipoprotein E: Far more than a lipid transport protein. Annu. Rev. Genom. Hum. Genet. 2000;1:507–537. doi: 10.1146/annurev.genom.1.1.507. PubMed DOI

Beffert U., Stolt P.C., Herz J. Functions of lipoprotein receptors in neurons. J. Lipid Res. 2004;45:403–409. doi: 10.1194/jlr.R300017-JLR200. PubMed DOI

Cedazo-Minguez A. Apolipoprotein E and Alzheimer’s disease: Molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med. 2007;11:1227–1238. doi: 10.1111/j.1582-4934.2007.00130.x. PubMed DOI PMC

Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu. Rev. Med. 1996;47:387–400. doi: 10.1146/annurev.med.47.1.387. PubMed DOI

Bertram L., Tanzi R.E. The genetics of Alzheimer’s disease. Prog. Mol. Biol. Transl. Sci. 2012;107:79–100. PubMed

Slooter A.J., Cruts M., Kalmijn S., Hofman A., Breteler M.M., van Broeckhoven C., van Duijn C.M. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam study. Arch. Neurol. 1988;55:964–968. doi: 10.1001/archneur.55.7.964. PubMed DOI

Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J.C., Carrasquillo M.M., Abraham R., Hamshere M.L., Pahwa J.S., Moskvina V., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat. Genet. 2011;43:429–435. doi: 10.1038/ng.803. PubMed DOI PMC

Naj A.C., Jun G., Beecham G.W., Wang L.S., Vardarajan B.N., Buros J., Gallins P.J., Buxbaum J.D., Jarvik G.P., Crane P.K., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat. Genet. 2011;43:436–441. doi: 10.1038/ng.801. PubMed DOI PMC

Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., Jun G., Destefano A.L., Bis J.C., Beecham G.W., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 2013;45:1452–1458. doi: 10.1038/ng.2802. PubMed DOI PMC

Gandhi S., Wood N.W. Genome-wide association studies: The key to unlocking neurodegeneration? Nat. Neurosci. 2010;13:789–794. doi: 10.1038/nn.2584. PubMed DOI

Harold D., Abraham R., Haooingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat. Genet. 2009;41:1088–1093. doi: 10.1038/ng.440. PubMed DOI PMC

Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Teavernier B., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat. Genet. 2009;41:1094–1099. doi: 10.1038/ng.439. PubMed DOI

Chapuis J., Hansmannel F., Gistelinck M., Mounier A., van Cauwenberghe C., Kolen K.V., Geller F., Sottejeau Y., Harold D., Dourlen P., et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating Tau pathology. Mol. Psychiatry. 2013;18:1225–1234. doi: 10.1038/mp.2013.1. PubMed DOI PMC

Antúnez C., Boada M., González-Pérez A., Gayán J., Ramírez-Lorca R., Marín J., Hernández I., Moreno-Rey C., Morón F.J., López-Arrieta J., et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer’s disease. Genome Med. 2011;3:33. doi: 10.1186/gm249. PubMed DOI PMC

Bradshaw E.M., Chibnik L.B., Keenan B.T., Ottoboni L., Raj T., Tang A., Rosenkrantz L.L., Imboywa S., Lee M., von Korff A., et al. CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology. Nat. Neurosci. 2013;16:848–850. doi: 10.1038/nn.3435. PubMed DOI PMC

Griciuc A., Serrano-Pozo A., Parrado A.R., Lesinski A.N., Asselin C.N., Mullin K., Hooli B., Choi S.H., Hyman B.T., Tanzi R.E. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid β. Neuron. 2013;78:631–643. doi: 10.1016/j.neuron.2013.04.014. PubMed DOI PMC

Karch C.M., Jeng A.T., Nowotny P., Cady J., Cruchaga C., Goate A.M. Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. PLoS ONE. 2012;7:e50976. doi: 10.1371/journal.pone.0050976. PubMed DOI PMC

Guerreiro R., Wojtas A., Bras J., Carrsquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 2013;368:117–127. doi: 10.1056/NEJMoa1211851. PubMed DOI PMC

Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. Engl. J. Med. 2013;368:107–116. doi: 10.1056/NEJMoa1211103. PubMed DOI PMC

Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., et al. The neuronal sortilin-related SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007;39:168–177. doi: 10.1038/ng1943. PubMed DOI PMC

Miyashita A., Koike A., Jun G., Wang L.S., Takahashi S., Matsubara E., Kawarabayashi T., Shoji M., Tomita N., Arai H., et al. SORL1 is genetically associated with late-onset Alzheimer’s disease in Japanese, Koreans and Caucasians. PLoS ONE. 2013;8:e58618. doi: 10.1371/journal.pone.0058618. PubMed DOI PMC

Jones L., Holmans P.A., Hamshere M.L., Harold D., Moskvina V., Ivanov D., Pocklington A., Abraham R., Hollingworth P., Sims R., et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS ONE. 2010;5:e13950. doi: 10.1371/journal.pone.0013950. PubMed DOI PMC

De Strooper B. Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiol. Rev. 2010;90:465–494. doi: 10.1152/physrev.00023.2009. PubMed DOI

Santos C.R.A., Cardoso I., Goncalves I. Key enzymes and proteins in amyloid-β production and clearance. In: de la Monte S., editor. Alzheimer’s Disease Pathogenesis—Core Concepts, Shifting Paradigms and Therapeutic Targets. InTech; Shanghai, China: 2011. pp. 53–86.

Nikolaev A., McLaughlin T., O’Leary D.D., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981–989. doi: 10.1038/nature07767. PubMed DOI PMC

Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 1991;12:383–388. doi: 10.1016/0165-6147(91)90609-V. PubMed DOI

Selkoe D.J. The molecular pathology of Alzheimer’s disease. Neuron. 1991;6:487–498. doi: 10.1016/0896-6273(91)90052-2. PubMed DOI

Hardy J.A. Higgins, G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science. 1992;256:184–185. doi: 10.1126/science.1566067. PubMed DOI

Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994. PubMed DOI

Giannakopoulos P., Herrmann F.R., Bussiere T., Bouras C., Kovari E., Perl D.P., Mossison J.H., Gold G., Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003;60:1495–1500. doi: 10.1212/01.WNL.0000063311.58879.01. PubMed DOI

Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA. 2000;283:1571–1577. doi: 10.1001/jama.283.12.1571. PubMed DOI

McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Master C.L. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann. Neurol. 1999;46:860–866. doi: 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M. PubMed DOI

Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535–539. doi: 10.1038/416535a. PubMed DOI

Cleary J.P., Walsh D.M., Hofmeister J.J., Schankar G.M., Kukskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 2005;8:79–84. doi: 10.1038/nn1372. PubMed DOI

Bitan G., Fradinger E.A., Spring S.M., Teplow D.B. Neurotoxic protein oligomers—What you see is not always what you get. Amyloid. 2005;12:88–95. doi: 10.1080/13506120500106958. PubMed DOI

Zhao W.Q., de Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid β oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008;22:246–560. doi: 10.1096/fj.06-7703com. PubMed DOI

Zhao W.Q. Alkon, D.L. Role of insulin and insulin receptor in learning and memory. Mol. Cell. Endocrinol. 2001;177:125–134. doi: 10.1016/S0303-7207(01)00455-5. PubMed DOI

Barry A.E., Klyubin I., McDonald J.M., Mably A.J., Farrell M.A., Scott M., Walsh D.M., Rowan M.J. Alzheimer’s disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 2011;31:7259–7263. doi: 10.1523/JNEUROSCI.6500-10.2011. PubMed DOI PMC

Um J.W., Nygaard H.B., Heiss J.K., Kostylev M.A., Stagi M., Vortmeyer A., Wisniewski T., Gunther E.C., Strittmatter S.M. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat. Neurosci. 2012;15:1227–1235. doi: 10.1038/nn.3178. PubMed DOI PMC

Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. USA. 2011;108:5819–5824. doi: 10.1073/pnas.1017033108. PubMed DOI PMC

Kayed R., Lasagna-Reeves C.A. Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 2013;33:S67–S78. PubMed

Pei J.J., Hugon J. mTOR-dependent signalling in Alzheimer’s disease. J. Cell. Mol. Med. 2008;12:2525–2532. doi: 10.1111/j.1582-4934.2008.00509.x. PubMed DOI PMC

Foster J.K., Verdile G., Bates K.A., Martins R.N. Immunization in Alzheimer’s disease: Naive hope or realistic clinical potential? Mol. Psychiatry. 2009;14:239–251. doi: 10.1038/mp.2008.115. PubMed DOI

Farlow M., Arnold S.E., van Dyck C.H., Aisen P.S., Snider B.J., Porsteinsson A.P., Friedrich S., Dean R.A., Gonzales C., Sethuraman G., et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 2012;8:261–271. doi: 10.1016/j.jalz.2011.09.224. PubMed DOI

Goure W.F., Krafft G.A., Jerecic J., Hefti F. Targeting the proper amyloid-β neuronal toxins: A path forward for Alzheimer’s disease immunotherapeutics. Alzheimers Res. Ther. 2014;6:42. doi: 10.1186/alzrt272. PubMed DOI PMC

Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., Raman R., Sun X., Aisen P.S., et al. Alzheimer’s Disease Cooperative Study Steering Committee, Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 2014;370:311–321. doi: 10.1056/NEJMoa1312889. PubMed DOI

Siemers E.R., Sundell K.L., Carlson C., Case M., Sethuraman G., Liu-Seifert H., Dowsett S.A., Pontecorvo M.J., Dean R.A., Demattos R. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 2015 doi: 10.1016/j.jalz.2015.06.1893. PubMed DOI

Wisniewski T., Goni F. Immunotherapy for Alzheimer’s disease. Biochem. Pharmacol. 2014;88:499–507. doi: 10.1016/j.bcp.2013.12.020. PubMed DOI PMC

Carrillo M.C., Brashear H.R., Logovinsky V., Ryan J.M., Feldman H.H., Siemers E.R., Abushakra S., Hartley D.M., Petersen R.C., Khachaturian A.S., et al. Can we prevent Alzheimer’s disease? Secondary “prevention” trials in Alzheimer’s disease. Alzheimers Dement. 2013;9:123–131. doi: 10.1016/j.jalz.2012.12.004. PubMed DOI

Lindwall G., Cole R.D. Phosphorylation affects the ability of Tau protein to promote microtubule assembly. J. Biol. Chem. 1984;259:5301–5305. PubMed

Caceres A., Kosik K.S. Inhibition of neurite polarity by Tau antisense oligonucleotides in primary cerebellar neurons. Nature. 1990;343:461–463. doi: 10.1038/343461a0. PubMed DOI

Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121–1159. doi: 10.1146/annurev.neuro.24.1.1121. PubMed DOI

Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B.I., Geschwind D.H., Bird T.D., McKeel D., Goate A., et al. Mutation-specific functional impairments in distinct Tau isoforms of hereditary FTDP-17. Science. 1998;282:1914–1917. doi: 10.1126/science.282.5395.1914. PubMed DOI

Garcia M.L., Cleveland D.W. Going new places using an old MAP: Tau, microtubules and human neurodegenerative disease. Curr. Opin. Cell Biol. 2001;13:41–48. doi: 10.1016/S0955-0674(00)00172-1. PubMed DOI

Gomez-Isla T., Hollister R., West H., Mui S., Growdon J.H., Petersen R.C., Parisi J.E., Hyman B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann. Neurol. 1997;41:17–24. doi: 10.1002/ana.410410106. PubMed DOI

Lasagna-Reeves C.A., Castillo-Carranza D.L., Sengupta U., Guerrero-Munoz M.J., Kiritoshi T., Neugebauer V., Jackson G.R., Kayed R. Alzheimer brain-derived Tau oligomers propagate pathology from endogenous Tau. Sci. Rep. 2012;2:700. doi: 10.1038/srep00700. PubMed DOI PMC

Berger Z., Roder H., Hanna A., Carlson A., Rangachari V., Yue M., Wszolek Z., Ashe K., Knight J., Dickson D., et al. Accumulation of pathological Tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 2007;27:3650–3662. doi: 10.1523/JNEUROSCI.0587-07.2007. PubMed DOI PMC

Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 2007;8:663–672. doi: 10.1038/nrn2194. PubMed DOI

Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337–351. doi: 10.1016/j.neuron.2007.01.010. PubMed DOI

Sergeant N., Delacourte A., Buee L. Tau protein as a differential biomarker of tauopathies. Biochim. Biophys. Acta. 2005;1739:179–197. doi: 10.1016/j.bbadis.2004.06.020. PubMed DOI

Wilhelmsen K.C., Lynch T., Pavlou E., Higgins M., Nygaard T.G. Localization of disinhibition–dementia–parkinsonism–amyotrophy complex to 17q2-22. Am. J. Hum. Genet. 1994;55:1159–1165. PubMed PMC

Goedert M. Tau gene mutations and their effects. Mov. Disord. 2005;12:45–52. doi: 10.1002/mds.20539. PubMed DOI

Small S.A., Duff K. Linking Aβ and Tau in late-onset Alzheimer’s disease: A dual pathway hypothesis. Neuron. 2008;60:534–542. doi: 10.1016/j.neuron.2008.11.007. PubMed DOI PMC

Castellani R.J., Perry G. The complexities of the pathology—pathogenesis relationship in Alzheimer disease. Biochem. Pharmacol. 2014;88:671–676. doi: 10.1016/j.bcp.2014.01.009. PubMed DOI

Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216–223. doi: 10.1016/S0140-6736(08)61075-2. PubMed DOI

Rosenmann H., Grigoriadis N., Karussis D., Boimel M., Touloumi O., Ovadia H., Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal Tau protein. Arch. Neurol. 2006;63:1459–1467. doi: 10.1001/archneur.63.10.1459. PubMed DOI

Boutajangout A., Ingadottir J., Davies P., Sigurdsson E.M. Passive immunization targeting pathological phospho-Tau protein in a mouse model reduces functional decline and clears Tau aggregates from the brain. J. Neurochem. 2011;118:658–667. doi: 10.1111/j.1471-4159.2011.07337.x. PubMed DOI PMC

Chai X., Wu S., Murray T.K., Kinley R., Cella C.V., Sims H., Buckner N., Hanmer J., Davies P., O’Neill M.J., et al. Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 2011;286:34457–34467. doi: 10.1074/jbc.M111.229633. PubMed DOI PMC

Morley J.E., Farr S.A. The role of amyloid-β in the regulation of memory. Biochem. Pharmacol. 2014;88:479–485. doi: 10.1016/j.bcp.2013.12.018. PubMed DOI

Muller U.C., Zheng H. Physiological functions of APP family proteins. Cold Spring Harb. Perspect. Med. 2012;2 doi: 10.1101/cshperspect.a006288. PubMed DOI PMC

Ke Y.D., Suchowerska A.K., van der Hoven J., de Silva D.M., Wu C.W., van Eersel J., Ittner A., Ittner L.M. Lessons from Tau-deficient mice. Int. J. Alzheimers Dis. 2012;2012 doi: 10.1155/2012/873270. PubMed DOI PMC

Taylor R.C., Dillin A. Aging as an event of proteostasis collapse. Cold Spring Harb. Perspect. Biol. 2011;3 doi: 10.1101/cshperspect.a004440. PubMed DOI PMC

Schroder M., Kaufman R.J. The mammalian unfolded protein response. Annu. Rev. Biochem. 2005;74:739–789. doi: 10.1146/annurev.biochem.73.011303.074134. PubMed DOI

Urra H., Dufey E., Lisbona F., Rojas-Rivera D., Hetz C. When ER stress reaches a dead end. Biochim. Biophys. Acta. 2013;1833:3507–3517. doi: 10.1016/j.bbamcr.2013.07.024. PubMed DOI

Salminen A., Kauppinen A., Suuronen T., Kaarniranta K., Ojala J. ER stress in Alzheimer’s disease: A novel neuronal trigger for inflammation and Alzheimer’s pathology. J. Neuroinflamm. 2009;6:41. doi: 10.1186/1742-2094-6-41. PubMed DOI PMC

Li G., Mongillo M., Chin K.T., Harding H., Ron D., Marks A.R., Tabas I. Role of ERO1-α-mediated stimulation of inositol 1,4,5-tirphoate receptor activity in endoplasmic reticulum stress-induced apoptosis. J. Cell Biol. 2009;186:783–792. doi: 10.1083/jcb.200904060. PubMed DOI PMC

Urano F., Wang X., Bertolotti A., Zhang Y., Chung P., Harding H.P., Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 2000;287:664–666. doi: 10.1126/science.287.5453.664. PubMed DOI

Sekine Y., Takeda K., Ichijo H. The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. Curr. Mol. Med. 2006;6:87–97. doi: 10.2174/156652406775574541. PubMed DOI

Kelleher I., Garwood C., Hanger D.P., Anderton B.H., Noble W. Kinase activities increase during the development of tauopathy in htau mice. J. Neurochem. 2007;103:2256–2267. doi: 10.1111/j.1471-4159.2007.04930.x. PubMed DOI

Ploia C., Antoniou X., Sclip A., Grande V., Cardinetti D., Colombo A., Canu N., Benussi L., Ghidoni R., Forloni G., et al. JNK plays a key role in Tau hyperphosphorylation in Alzheimer’s disease models. J. Alzheimers Dis. 2011;26:315–329. PubMed

Cuanalo-Contreras K., Mukherjee A., Soto C. Role of protein misfolding and proteostasis deficiency in protein misfolding diseases and aging. Int. J. Cell Biol. 2013;2013 doi: 10.1155/2013/638083. PubMed DOI PMC

Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu. Rev. Immunol. 2009;27:693–733. doi: 10.1146/annurev.immunol.021908.132641. PubMed DOI

Rossner S., Sastre M., Bourne K., Lichtenthaler S.F. Transcriptional and translational regulation of BACE1 expression—Implications for Alzheimer’s disease. Prog. Neurobiol. 2006;79:95–111. doi: 10.1016/j.pneurobio.2006.06.001. PubMed DOI

Resende R., Moreira P.I., Proenca T., Deshpande A., Busciglio J., Pereira C., Oliveira C.R. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic. Biol. Med. 2008;44:2051–2057. doi: 10.1016/j.freeradbiomed.2008.03.012. PubMed DOI

Morawe T., Hiebel C., Kern A., Behl C. Protein homeostasis, aging and Alzheimer’s disease. Mol. Neurobiol. 2012;46:41–54. doi: 10.1007/s12035-012-8246-0. PubMed DOI PMC

Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148:1204–1222. doi: 10.1016/j.cell.2012.02.040. PubMed DOI PMC

Kakimura J., Kitamura Y., Takata K., Umeki M., Suzuki S., Shibagaki K., Taniguchi T., Nomura Y., Gebicke-Haerter P.J., Smith M.A., et al. Microglial activation and amyloid-β clearance induced by exogenous heat-shock proteins. FASEB J. 2002;16:601–603. doi: 10.1096/fj.01-0530fje. PubMed DOI

Koren J., III, Jinwal U.K., Lee D.C., Jones J.R., Shults C.L., Johnson A.G., Anderson L.J., Dickey C.A. Chaperone signalling complexes in Alzheimer’s disease. J. Cell. Mol. Med. 2009;13:619–630. doi: 10.1111/j.1582-4934.2008.00557.x. PubMed DOI PMC

Wilhelmus M.M., de Waal R.M., Verbeek M.M. Heat shock proteins and amateur chaperones in amyloid-β accumulation and clearance in Alzheimer’s disease. Mol. Neurobiol. 2007;35:203–216. doi: 10.1007/s12035-007-0029-7. PubMed DOI PMC

Jinwal U.K., O’Leary J.C., III, Borysov S.I., Jones J.R., Li Q., Koren J., III, Abisambra J.F., Vestal G.D., Lawson L.Y., Johnson A.G., et al. Hsc70 rapidly engages Tau after microtubule destabilization. J. Biol. Chem. 2010;285:16798–16805. doi: 10.1074/jbc.M110.113753. PubMed DOI PMC

Sahara N., Murayama M., Mizoroki T., Urushitani M., Imai Y., Takahashi R., Murata S., Tanaka K., Takashima A. In vivo evidence of CHIP up-regulation attenuating Tau aggregation. J. Neurochem. 2005;94:1254–1263. doi: 10.1111/j.1471-4159.2005.03272.x. PubMed DOI

Dickey C.A., Koren J., Zhang Y.J., Xu Y.F., Jinwal U.K., Birnbaum M.J., Monks B., Sun M., Cheng J.Q., Patterson C., et al. Akt and CHIP coregulate Tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. USA. 2008;105:3622–3627. doi: 10.1073/pnas.0709180105. PubMed DOI PMC

Martin M., Dotti C.G., Ledesma M.D. Brain cholesterol in normal and pathological aging. Biochim. Biophys. Acta. 2010;1801:934–944. doi: 10.1016/j.bbalip.2010.03.011. PubMed DOI

Wang H., Eckel R.H. What are lipoproteins doing in the brain? Trends Endocrinol. Metab. 2014;25:8–14. doi: 10.1016/j.tem.2013.10.003. PubMed DOI PMC

Wood W.G., Schroeder F., Igbavboa U., Avdulov N.A., Chochina S.V. Brain membrane cholesterol domains, aging and amyloid β-peptides. Neurobiol. Aging. 2002;23:685–694. doi: 10.1016/S0197-4580(02)00018-0. PubMed DOI

Ariga T., Wakade C., Yu R.K. The pathological roles of ganglioside metabolism in Alzheimer’s disease: Effects of gangliosides on neurogenesis. Int. J. Alzheimers Dis. 2011;2011:193618. doi: 10.4061/2011/193618. PubMed DOI PMC

Kakio A., Nishimoto S.I., Yanagisawa K., Kazutsumi Y., Matsuzaki K. Cholesterol-dependent formation on GM1 ganglioside-bound amyloid β-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem. 2001;276:24985–24990. doi: 10.1074/jbc.M100252200. PubMed DOI

Fantini J., Yahi N., Garmy N. Cholesterol accelerates the binding of Alzheimer’s β-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation. Front. Physiol. 2013;4:120. doi: 10.3389/fphys.2013.00120. PubMed DOI PMC

Yuyama K., Yanagisawa K. Sphingomyelin accumulation provides a favorable milieu for GM1 ganglioside-induced assembly of amyloid β-protein. Neurosci. Lett. 2010;481:168–172. doi: 10.1016/j.neulet.2010.06.080. PubMed DOI

Allen J.A., Halverson-Tamboli R.A., Rasenick M.M. Lipid raft microdomains and neurotransmitter signalling. Nat. Rev. Neurosci. 2007;8:128–140. doi: 10.1038/nrn2059. PubMed DOI

Hanzal-Bayer M.F., Hancock J.F. Lipid rats and membrane traffic. FEBS Lett. 2007;581:2098–2104. doi: 10.1016/j.febslet.2007.03.019. PubMed DOI

Cordy J.M., Hooper N.M., Turner A.J. The involvement of lipid rafts in Alzheimer’s disease. Mol. Membr. Biol. 2006;23:111–122. doi: 10.1080/09687860500496417. PubMed DOI

Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. USA. 2001;98:5815–5820. doi: 10.1073/pnas.081612998. PubMed DOI PMC

Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003;160:113–123. doi: 10.1083/jcb.200207113. PubMed DOI PMC

Hicks D.A., Nalivaeva N.N., Turner A.J. Lipid rafts and Alzheimer’s disease: Protein–lipid interactions and perturbation of signaling. Front. Physiol. 2012;3:189. doi: 10.3389/fphys.2012.00189. PubMed DOI PMC

Grimm M.O., Kuchenbecker J., Rothhaar T.L., Grosgen S., Hundsdorfer B., Burg V.K., Friess P., Muller U., Grimm H.S., Riemenschneider M., et al. Plasmalogen synthesis is regulated via alkyl-dihydorxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer’s disease. J. Neurochem. 2011;116:916–925. doi: 10.1111/j.1471-4159.2010.07070.x. PubMed DOI

Rothhaar T.L., Grosgen S., Haupenthal V.J., Burg V.K., Hundsdorfer B., Mett J., Riemenschneider M., Grimm H.S., Hartmann T., Grimm M.O. Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer’s disease. Sci. World J. 2012;2012 doi: 10.1100/2012/141240. PubMed DOI PMC

Ghosal K., Vogt D.L., Liang M., Shen Y., Lamb B.T., Pimplikar S.W. Alzheimer’s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc. Natl. Acad. Sci. USA. 2009;106:18367–18372. PubMed PMC

Fabelo N., Marin V., Marin R., Moreno D., Ferrer I., Diaz M. Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer’s disease and facilitates APP/BACE1 interactions. Neurobiol. Aging. 2014;35:1801–1812. doi: 10.1016/j.neurobiolaging.2014.02.005. PubMed DOI

Geekiyanage H., Upadhye A., Chan C. Inhibition of serine palmitoyltransferase reduces Aβ and Tau hyperphosphorylation in a murine model: A safe therapeutic strategy for Alzheimer’s disease. Neurobiol. Aging. 2013;34:2037–2051. PubMed PMC

Riemann D., Hansen G.H., Niels-Christiansen L.L., Thorsen E., Immerdal L., Santos A.N., Kehlen A., Langner J., Danielsen E.M. Caveolae/lipid rafts in fibroblast-like synoviocytes: Ectopeptidase-rich membrane microdomains. Biochem. J. 2001;354:47–55. doi: 10.1042/bj3540047. PubMed DOI PMC

Kawarabayashi T., Shoji M., Younkin L.H., Wen-Lang L., Dickson D.W., Murakami T., Matsubara E., Abe K., Ashe K.H., Younkin S.G. Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated Tau accumulation in the Tg2576 mouse model of Alzheimer’s disease. J. Neurosci. 2004;24:3801–3809. doi: 10.1523/JNEUROSCI.5543-03.2004. PubMed DOI PMC

Bulloj A., Leal M.C., Surace E.I., Zhang X., Xu H., Ledesma M.D., Castano E.M., Morelli L. Detergent resistant membrane-associated IDE in brain tissue and cultured cells: Relevance to Aβ and insulin degradation. Mol. Neurodegener. 2008;3:22. doi: 10.1186/1750-1326-3-22. PubMed DOI PMC

Parkin E.T., Watt N.T., Hussain I., Eckman E.A., Eckman C.B., Manson J.C., Baybutt H.N., Turner A.J., Hooper N.M. Cellular prion protein regulates β-secretase cleavage of the Alzheimer’s amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 2007;104:11062–11067. doi: 10.1073/pnas.0609621104. PubMed DOI PMC

Prybylowski K., Chang K., Sans N., Kan L., Vicini S., Wenthold R.J. The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron. 2005;47:845–857. doi: 10.1016/j.neuron.2005.08.016. PubMed DOI PMC

Um J.W., Strittmatter S.M. Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion. 2013;7:37–41. doi: 10.4161/pri.22212. PubMed DOI PMC

De Calignon A., Polydoro M., Suarez-Calvet M., William C., Adamowicz D.H., Kopeikina K.J., Pitstick R., Sahara N., Ashe K.H., Carlson G.A., et al. Propagation of Tau pathology in a model of early Alzheimer’s disease. Neuron. 2012;73:685–697. doi: 10.1016/j.neuron.2011.11.033. PubMed DOI PMC

Ronicke R., Mikhaylova M., Ronicke S., Meinhardt J., Schroder U.H., Fandrich M., Reiser G., Kreutz M.R., Reymann K.G. Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-cnotaining NMDA receptors. Neurobiol. Aging. 2011;32:2219–2228. doi: 10.1016/j.neurobiolaging.2010.01.011. PubMed DOI

Williamson R., Usardi A., Hanger D.P., Anderton B.H. Membrane-bound β-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J. 2008;22:1552–1559. doi: 10.1096/fj.07-9766com. PubMed DOI

Gimbel D.A., Nygaard H.B., Coffey E.E., Gunther E.C., Lauren J., Gimbel Z.A., Strittmatter S.M. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 2010;30:6367–6374. doi: 10.1523/JNEUROSCI.0395-10.2010. PubMed DOI PMC

Balducci C., Beeg M., Stravalaci M., Bastone A., Sclip A., Biasini E., Tapella L., Colombo L., Manzoni C., Borsello T., et al. Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. USA. 2010;107:2295–2300. doi: 10.1073/pnas.0911829107. PubMed DOI PMC

Calella A.M., Farinelli M., Nuvolone M., Mirante O., Moos R., Falsig J., Mansuy I.M., Aguzzi A. Prion protein and Aβ-related synaptic toxicity impairment. EMBO Mol. Med. 2010;2:306–314. doi: 10.1002/emmm.201000082. PubMed DOI PMC

Kudo W., Lee H.P., Zou W.Q., Wang X., Perry G., Zhu X., Smith M.A., Petersen R.B., Lee H.G. Cellular prion protein is essential for oligomeric amyloid-β-induced neuronal cell death. Hum. Mol. Genet. 2012;21:1138–1144. doi: 10.1093/hmg/ddr542. PubMed DOI PMC

Nicoll A.J., Panico S., Freir D.B., Wright D., Terry C., Risse E., Herron C.E., O’Malley T., Wadsworth J.D., Farrow M.A., et al. Amyloid-β nanotubes are associated with prion protein-dependent synaptotoxicity. Nat. Commun. 2013;4:2416. doi: 10.1038/ncomms3416. PubMed DOI PMC

Hernandez P., Lee G., Sjoberg M., Maccioni R.B. Tau phosphorylation by Cdk5 and Fyn in response to amyloid peptide Abera (25–35): Involvement of lipid rafts. J. Alzheimers Dis. 2009;16:149–156. PubMed

Sui Z., Kovacs A.D., Maggirwar S.B. Recruitment of active glycogen synthase kinase-3 into neuronal lipid rafts. Biochem. Biophys. Res. Commun. 2006;345:1643–1648. doi: 10.1016/j.bbrc.2006.05.087. PubMed DOI

Nikolic M., Dudek H., Kwon Y.T., Ramos Y.F., Tsai L.H. The Cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 1996;10:816–825. doi: 10.1101/gad.10.7.816. PubMed DOI

Kimura T., Ishiguro K., Hisanaga S. Physiological and pathological phosphorylation of Tau by Cdk5. Front. Mol. Neurosci. 2014;7:65. doi: 10.3389/fnmol.2014.00065. PubMed DOI PMC

Shukla V., Skuntz S., Pant H.C. Deregulated Cdk5 activity is involved in inducing Alzheimer’s disease. Arch. Med. Res. 2012;43:655–662. doi: 10.1016/j.arcmed.2012.10.015. PubMed DOI PMC

Mazanetz M.P., Fischer P.M. Untangling Tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 2007;6:464–479. doi: 10.1038/nrd2111. PubMed DOI

Lee G., Thangavel R., Sharma V.M., Litersky J.M., Bhaskar K., Fang S.M., Do L.H., Andreadis A., van Hoesen G., Ksiezak-Reding H. Phosphorylation of Tau by fyn: Implications of Alzheimer’s disease. J. Neurosci. 2004;24:2304–2312. doi: 10.1523/JNEUROSCI.4162-03.2004. PubMed DOI PMC

Bhaskar K., Yen S.H., Lee G. Disease-related modifications in Tau affect the interaction between Fyn and Tau. J. Biol. Chem. 2005;280:35119–35125. doi: 10.1074/jbc.M505895200. PubMed DOI

Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., et al. Dendritic function of Tau mediates amyloid-β toxicity in Alzheimer’s disease mouse models. Cell. 2010;142:387–397. doi: 10.1016/j.cell.2010.06.036. PubMed DOI

Usardi A., Pooler A.M., Seereeram A.M., Reynolds C.H., Derkinderen P., Anderton B., Hanger D.P., Noble W., Williamson R. Tyrosine phosphorylation of Tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau. FEBS J. 2011;278:2927–2937. doi: 10.1111/j.1742-4658.2011.08218.x. PubMed DOI

Liu F., Shi J., Tranimukai H., Gu J., Gu J., Grundke-Iqbal I., Iqbal K., Gong C.X. Reduced O-GlcNAcylation links lower brain glucose metabolism and Tau pathology in Alzheimer’s disease. Brain. 2009;132:1820–1832. doi: 10.1093/brain/awp099. PubMed DOI PMC

Velliquette R.A., O’Connor T., Vassar R. Energy inhibition elevates β-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer’s disease pathogenesis. J. Neurosci. 2005;25:10874–10883. doi: 10.1523/JNEUROSCI.2350-05.2005. PubMed DOI PMC

O’Connor T., Sadleir K.R., Maus E., Velliquette R.A., Zhao J., Cole S.L., Eimer W.A., Hitt B., Bembinster L.A., Lammich S., et al. Phosphorylation of the translation initiation factor eIF2α increases BACE1 levels and promotes amyloidogenesis. Neuron. 2008;60:988–1009. doi: 10.1016/j.neuron.2008.10.047. PubMed DOI PMC

Ankarcrona M., Mangialasche F., Winblad B. Rethinking Alzheimer’s disease therapy: Are mitochondria the key? J. Alzheimers Dis. 2010;20:S579–S590. PubMed

Jacobsen K.T., Iverfeldt K. O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-β precursor protein (APP) Biochem. Biophys. Res. Commun. 2011;404:882–886. doi: 10.1016/j.bbrc.2010.12.080. PubMed DOI

Liu K., Paterson A.J., Zhang F., McAndrew J., Fukuchi K., Wyss J.M., Peng L., Hu Y., Kudlow J.E. Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J. Neurochem. 2004;89:1044–1055. doi: 10.1111/j.1471-4159.2004.02389.x. PubMed DOI

Brister M.A., Pandey A.K., Bielska A.A., Zondlo N.J. OGlcNAcylation and phosphorylation have opposing structural effects in Tau: Phosphothreonine induces particular conformational order. J. Am. Chem. Soc. 2014;136:3803–3816. doi: 10.1021/ja407156m. PubMed DOI PMC

Iqbal K., Alonso Adel C., Chen S., Chohan M.O., El-Akkad E., Gong C.X., Khatoon S., Li B., Liu F., Rahman A., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta. 2005;1739:198–210. doi: 10.1016/j.bbadis.2004.09.008. PubMed DOI

Liu F., Iqbal K., Grundke-Igbal I., Hart G.W., Gong C.X. O-GlcNAcylation regulates phosphorylation of Tau: A mechanism involved in Alzheimer’s disease. Proc. Natl. Acad. Sci. USA. 2004;101:10804–10809. doi: 10.1073/pnas.0400348101. PubMed DOI PMC

Tallent M.K., Varghis N., Skorobogatko Y., Hernandez-Cuebas L., Whelan K., Vocadlo D.J., Vosseller K. In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J. Biol. Chem. 2009;284:174–181. doi: 10.1074/jbc.M807431200. PubMed DOI

Gella A., Durany N. Oxidative stress in Alzheimer disease. Cell Adh. Migr. 2009;3:88–93. doi: 10.4161/cam.3.1.7402. PubMed DOI PMC

Pocernich C.B., Butterfield D.A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim. Biophys. Acta. 2012;1822:625–630. PubMed PMC

Liu R., Choi J. Age-associated decline in γ-glutamylcysteine synthetase gene expression in rats. Free Radic. Biol. Med. 2000;28:566–574. doi: 10.1016/S0891-5849(99)00269-5. PubMed DOI

Saharan S., Mandal P.K. The emerging role of glutathione in Alzheimer’s disease. J. Alzheimers Dis. 2014;40:519–529. PubMed

Lee M., Cho T., Jantaratnotai N., Wang Y.T., McGeer E., McGeer P.L. Depletion of GSH in glial cells induces neurotoxicity: Relevance to aging and degenerative neurological diseases. FASEB J. 2010;24:2533–2545. doi: 10.1096/fj.09-149997. PubMed DOI

Shen C., Chen Y., Liu H., Zhang K., Zhang T., Lin A., Jing N. Hydrogen peroxide promotes Aβ production through JNK-dependent activation of γ-secretase. J. Biol. Chem. 2008;283:17721–17730. doi: 10.1074/jbc.M800013200. PubMed DOI PMC

Anantharaman M., Tangpong J., Keller J.N., Murphy M.P., Markesbery W.R., Kiningham K.K., St., Clair D.K. β-amyloid mediated nitration of manganese superoxide dismutase: Implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer’s disease. Am. J. Pathol. 2006;168:1608–1617. doi: 10.2353/ajpath.2006.051223. PubMed DOI PMC

Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci. 1998;158:47–52. doi: 10.1016/S0022-510X(98)00092-6. PubMed DOI

Atwood C.S., Scarpa R.C., Huang X., Moir R.D., Jones W.D., Fairlie D.P., Tanzi R.E., Bush A.I. Characterization of copper interactions with Alzheimer amyloid β peptides: Identification of an attomolar-affinity copper binding site on amyloid β1-42. J. Neurochem. 2000;75:1219–1233. doi: 10.1046/j.1471-4159.2000.0751219.x. PubMed DOI

Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E., et al. Cu(II) potentiation of Alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 1999;274:37111–37116. doi: 10.1074/jbc.274.52.37111. PubMed DOI

Al-Hilaly Y.K., Williams T.L., Stewart-Parker M., Ford L., Skaria E., Cole M., Bucher W.G., Morris K.L., Sada A.A., Thorpe J.R., et al. A central role for dityrosine crosslinking of amyloid-β in Alzheimer’s disease. Acta Neuropathol. Commun. 2013;1:83. doi: 10.1186/2051-5960-1-83. PubMed DOI PMC

Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 1998;18:8126–8132. PubMed PMC

Cuajungco M.P., Goldstein L.E., Nunomura A., Smith M.A., Lim J.T., Atwood C.S., Huang X., Farrag Y.W., Perry G., Bush A.I. Evidence that the β-amyloid plaques of Alzheimer’s disease represent the redox-silencing and entombment of Aβ by zinc. J. Biol. Chem. 2000;275:19439–19442. doi: 10.1074/jbc.C000165200. PubMed DOI

Craddock T.J., Tuszynski J.A., Chopra D., Casey N., Goldstein L.E., Hameroff S.R., Tanzi R.E. The zinc dyshoemostasis hypothesis of Alzheimer’s disease. PLoS ONE. 2012;7:e33552. doi: 10.1371/journal.pone.0033552. PubMed DOI PMC

Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382:685–691. doi: 10.1038/382685a0. PubMed DOI

Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M., Nawroth P.P. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 2005;83:876–886. doi: 10.1007/s00109-005-0688-7. PubMed DOI

Srikanth V., Maczurek A., Phan T., Steele M., Westcott B., Juskiw D., Munch G. Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol. Aging. 2011;32:763–777. doi: 10.1016/j.neurobiolaging.2009.04.016. PubMed DOI

Valente T., Gella A., Fernandez-Busquets X., Unzeta M., Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol. Dis. 2010;37:67–76. doi: 10.1016/j.nbd.2009.09.008. PubMed DOI

Cho H.J., Son S.M., Jin S.M., Hong H.S., Shin D.H., Kim S.J., Huh K., Mook-Jung I. RAGE regulates BACE1 and Aβ generation via NFAT1 activation in Alzheimer’s disease animal model. FASEB J. 2009;23:2639–2649. doi: 10.1096/fj.08-126383. PubMed DOI

Yan S.D., Bierhaus A., Nawroth P.P., Stern D.M. RAGE and Alzheimer’s disease: A progression factor for amyloid-β-induced cellular perturbation? J. Alzheimers Dis. 2009;16:833–843. PubMed PMC

Martel C.L., Mackic J.B., McComb J.G., Ghiso J., Zlokovic B.V. Blood–brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer’s amyloid β in guinea pigs. Neurosci. Lett. 1996;206:157–160. doi: 10.1016/S0304-3940(96)12462-9. PubMed DOI

Deane R., du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumlation in brain. Nat. Med. 2003;9:907–913. doi: 10.1038/nm890. PubMed DOI

Manolopoulos K.N., Klotz L.O., Korsten P., Bornstein S.R., Barthel A. Linking Alzheimer’s disease to insulin resistance: The FoxO response to oxidative stress. Mol. Psychiatry. 2010;15:1046–1052. doi: 10.1038/mp.2010.17. PubMed DOI

Hardas S.S., Sultana R., Clark A.M., Beckett T.L., Szweda L.I., Murphy M.P., Butterfield D.A. Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol. 2013;1:80–85. doi: 10.1016/j.redox.2013.01.002. PubMed DOI PMC

Siegel S.J., Bieschke J., Powers E.T., Kelly J.W. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry. 2007;46:1503–1510. doi: 10.1021/bi061853s. PubMed DOI PMC

Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol. Aging. 1998;19:33–36. doi: 10.1016/S0197-4580(98)00009-8. PubMed DOI

Schulingkamp R.J., Pagano T.C., Hung D., Raffa R.B. Insulin receptors and insulin action in the brain: Review and clinical implications. Neurosci. Biobehav. Rev. 2000;24:855–872. doi: 10.1016/S0149-7634(00)00040-3. PubMed DOI

Dore S., Kar S., Quirion R. Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity. Proc. Natl. Acad. Sci. USA. 1997;94:4772–4777. doi: 10.1073/pnas.94.9.4772. PubMed DOI PMC

Fernandez A.M., Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 2012;13:225–239. doi: 10.1038/nrn3209. PubMed DOI

Wozniak M., Rydzewski B., Baker S.P., Raizada M.K. The cellular and physiological actions of insulin in the central nervous system. Neurochem. Int. 1993;22:1–10. doi: 10.1016/0197-0186(93)90062-A. PubMed DOI

Sesti G., Federici M., Hribal M.L., Lauro D., Sbraccia P., Lauro R. Defects of the isnulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001;15:2099–2111. doi: 10.1096/fj.01-0009rev. PubMed DOI

White M.F. Insulin signaling in health and disease. Science. 2003;302:1710–1711. doi: 10.1126/science.1092952. PubMed DOI

Schubert M., Brazil D.P., Burks D.J., Kushner J.A., Ye J., Flint C.L., Farhang-Fallah J., Dikkes P., Warot X.M., Rio C., et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes Tau phosphorylation. J. Neurosci. 2003;23:7084–7092. PubMed PMC

Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., Kondo T., Alber J., Galldiks N., Kustermann E., et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. USA. 2004;101:3100–3105. doi: 10.1073/pnas.0308724101. PubMed DOI PMC

Cheng C.M., Tseng V., Wang J., Wang D., Matyakhina L., Bondy C.A. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology. 2005;146:5086–5091. doi: 10.1210/en.2005-0063. PubMed DOI

Killick R., Scales G., Leroy K., Causevic M., Hooper C., Irvine E.E., Choudhury A.I., Drinkwater L., Kerr F., Al-Qassab H., et al. Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem. Biophys. Res. Commun. 2009;386:257–262. doi: 10.1016/j.bbrc.2009.06.032. PubMed DOI PMC

Moloney A.M., Griffin R.J., Timmons S., O’Connor R., Ravid R., O’Neil C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging. 2010;31:224–243. doi: 10.1016/j.neurobiolaging.2008.04.002. PubMed DOI

Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–789. doi: 10.1038/378785a0. PubMed DOI

Alessi D.R., Cohen P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 1998;8:55–62. doi: 10.1016/S0959-437X(98)80062-2. PubMed DOI

Frolich L., Blum-Degen D., Bernstein H.G., Engelsberger B.S., Humrich J., Laufer S., Muschner D., Thalheimer A., Turk A., Hoyer S., et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J. Neural Transm. 1998;105:423–438. doi: 10.1007/s007020050068. PubMed DOI

Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science. 1996;271:665–668. doi: 10.1126/science.271.5249.665. PubMed DOI

Aguirre V., Werner E.D., Giraud J., Lee Y.H., Shoelson S.E., White M.F. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 2002;277:1531–1537. doi: 10.1074/jbc.M101521200. PubMed DOI

Paz K., Hemi R., LeRoith D., Karasik A., Elhanany E., Kanety H., Zick Y. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Biol. Chem. 1997;272:29911–29918. doi: 10.1074/jbc.272.47.29911. PubMed DOI

De Felice F.G., Lourenco M.V., Ferreira S.T. How does brain insulin resistance develop in Alzheimer’s disease? Alzheimers Dement. 2014;10:S26–S32. doi: 10.1016/j.jalz.2013.12.004. PubMed DOI

Butterfield D.A., di Domenico F., Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochim. Biophys. Acta. 2014;1842:1693–1706. doi: 10.1016/j.bbadis.2014.06.010. PubMed DOI PMC

Dou J.T., Chen M., Dufour F., Alkon D.L., Zhao W.Q. Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn. Mem. 2005;12:646–655. doi: 10.1101/lm.88005. PubMed DOI PMC

Cole G.M., Frautschy S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s disease. Exp. Gerontol. 2007;42:10–21. doi: 10.1016/j.exger.2006.08.009. PubMed DOI

Zhao W.Q., Lacor P.N., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric Aβ. J. Biol. Chem. 2009;284:18742–18753. doi: 10.1074/jbc.M109.011015. PubMed DOI PMC

Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., Selkoe D.J. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 2000;20:1657–1665. PubMed PMC

Zhao L., Teter B., Morihara T., Lim G.P., Ambegaokar S.S., Ubeda O.J., Frautschy S.A., Cole G.M. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer’s disease intervention. J. Neurosci. 2004;24:11120–11126. doi: 10.1523/JNEUROSCI.2860-04.2004. PubMed DOI PMC

Reger M.A., Watson G.S., Green P.S., Baker L.D., Cholerton B., Fishel M.A., Plymate S.R., Cherrier M.M., Schellenberg G.D., Frey W.H., II, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J. Alzheimers Dis. 2008;13:323–331. PubMed PMC

Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Jin L.W., Kovacina K.S., Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer’s disease is associated with the apolipoprotein E-epsiron4 allele. Am. J. Pathol. 2003;162:313–319. doi: 10.1016/S0002-9440(10)63822-9. PubMed DOI PMC

Pelvig D.P., Pakkenberg H., Stark A.K., Pakkenberg B. Neocortical glial cell numbers in human brains. Neurobiol. Aging. 2008;29:1754–1762. doi: 10.1016/j.neurobiolaging.2007.04.013. PubMed DOI

Derecki N.C., Katzmarski N., Kipnis J., Meyer-Luehmann M. Microglia as a critical player in both developmental and late-life CNS pathogenesis. Acta Neuropathol. 2014;128:333–345. doi: 10.1007/s00401-014-1321-z. PubMed DOI PMC

Ekdahl C.T., Claasen J.H., Bonde S., Kokaia Z., Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. USA. 2003;100:13632–13637. doi: 10.1073/pnas.2234031100. PubMed DOI PMC

Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302:1760–1765. doi: 10.1126/science.1088417. PubMed DOI

Ziv Y., Ron N., Butovsky O., Landa G., Greenberg N., Cohen H., Kipnis J., Schwartz M. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 2006;9:268–275. doi: 10.1038/nn1629. PubMed DOI

Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on Tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003;23:1605–1611. PubMed PMC

Harrison J.K., Jiang Y., Chen S., Xia Y., Maciejewski D., McNamara R.K., Streit W.J., Salafranca M.N., Adhikari S., Thompson D.A., et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. USA. 1998;95:10896–10901. doi: 10.1073/pnas.95.18.10896. PubMed DOI PMC

Hatori H., Nagai A., Heisel R., Ryu J.K., Kim S.U. Fractalkine and fractalkine receptors in human neurons and glial cells. J. Neurosci. Res. 2002;69:418–426. doi: 10.1002/jnr.10304. PubMed DOI

Re D.B., Przedborski S. Fractalkine: Moving from chemotaxis to neuroprotection. Nat. Neurosci. 2006;9:859–861. PubMed

Lyons A., Lynch A.M., Downer E.J., Hanley R., O’Sullivan J.B., Smith A., Lynch M.A. Fractalkine-induced activation of the phosphatidylinositol-3 kinase pathway attenuates microglial activation in vivo and in vitro. J. Neurochem. 2009;110:1547–1556. doi: 10.1111/j.1471-4159.2009.06253.x. PubMed DOI

Deiva K., Geeraerts T., Salim H., Leclerc P., Hery C., Hugel B., Freyssinet J.M., Tardieu M. Fractalkine reduces N-methyl-d-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. Eur. J. Neurosci. 2004;20:3222–3232. doi: 10.1111/j.1460-9568.2004.03800.x. PubMed DOI

Limatola C., Lauro C., Catalano M., Ciotti M.T., Bertollini C., di Angelantonio S., Ragozzino D., Eusebi F. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J. Neuroimmunol. 2005;166:19–28. doi: 10.1016/j.jneuroim.2005.03.023. PubMed DOI

Kim T.S., Lim H.K., Lee J.Y., Kim D.J., Park S., Lee C., Lee C.U. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer’s disease. Neurosci. Lett. 2008;436:196–200. doi: 10.1016/j.neulet.2008.03.019. PubMed DOI

Cho S.H., Sun B., Zhou Y., Kauppinen T.M., Halabisky B., Wes P., Ransohoff R.M., Gan L. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2011;286:32713–32722. doi: 10.1074/jbc.M111.254268. PubMed DOI PMC

Lyons A., Downer E.J., Crotty S., Nolan Y.M., Mills K.H., Lynch M.A. CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: A role for IL-4. J. Neurosci. 2007;27:8309–8313. doi: 10.1523/JNEUROSCI.1781-07.2007. PubMed DOI PMC

Hernangomez M., Carrillo-Salinas F.J., Mecha M., Correa F., Mestre L., Loria F., Feliu A., Docagne F., Guaza C. Brain innate immunity in the regulation of neuroinflammation: Therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system. Curr. Pharm. Des. 2014;20:4707–4722. doi: 10.2174/1381612820666140130202911. PubMed DOI PMC

Cox F.F., Carney D., Miller A.M., Lynch M.A. CD200 fusion protein decreases microglial activation in the hippocampus of aged rats. Brain Behav. Immun. 2012;26:789–796. doi: 10.1016/j.bbi.2011.10.004. PubMed DOI

Frank M.G., Barrientos R.M., Biedenkapp J.C., Rudy J.W., Watkins L.R., Maier S.F. mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol. Aging. 2006;27:717–722. doi: 10.1016/j.neurobiolaging.2005.03.013. PubMed DOI

Walker D.G., Dalsing-Hernandez J.E., Campbell N.A., Lue L.F. Decreased expression of CD200 and CD200 receptor in Alzheimer’s disease: A potential mechanism leading to chronic inflammation. Exp. Neurol. 2009;215:5–19. doi: 10.1016/j.expneurol.2008.09.003. PubMed DOI PMC

Costello D.A., Lyons A., Denieffe S., Browne T.C., Cox F.F., Lynch M.A. Long term potentiation is impaired in membrane glycoprotein CD200-deficient mice: A role for Toll-like receptor activation. J. Biol. Chem. 2011;286:34722–34732. doi: 10.1074/jbc.M111.280826. PubMed DOI PMC

Okun E., Mattson M.P., Arumugam T.V. Involvement of Fc receptors in disorders of the central nervous system. Neuromol. Med. 2010;12:164–178. doi: 10.1007/s12017-009-8099-5. PubMed DOI PMC

Guilliams M., Bruhns P., Saeys Y., Hammad H., Lambrecht B.N. The function of Fcγ receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 2014;14:94–108. doi: 10.1038/nri3582. PubMed DOI

Gaikwad S., Larionov S., Wang Y., Dannenberg H., Matozaki T., Monsonego A., Thal D.R., Neumann H. Signal regulatory protein-β1: A microglial modulator of phagocytosis in Alzheimer’s disease. Am. J. Pathol. 2009;175:2528–2539. doi: 10.2353/ajpath.2009.090147. PubMed DOI PMC

Doens D., Fernandez P.L. Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis. J. Neuroinflamm. 2014;11:48. doi: 10.1186/1742-2094-11-48. PubMed DOI PMC

Qiu W.Q., Ye Z., Kholodenko D., Seubert P., Selkoe D.J. Degradation of amyloid β-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 1997;272:6641–6646. doi: 10.1074/jbc.272.10.6641. PubMed DOI

Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 1998;273:32730–32738. doi: 10.1074/jbc.273.49.32730. PubMed DOI

Carson J.A., Turner A.J. β-amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 2002;81:1–8. doi: 10.1046/j.1471-4159.2002.00855.x. PubMed DOI

Sakamoto M., Miyamoto K., Wu Z., Nakanishi H. Possible involvement of cathepsin B released by microglia in methylmercury-induced cerebellar pathological changes in the adult rat. Neurosci. Lett. 2008;442:292–296. doi: 10.1016/j.neulet.2008.07.019. PubMed DOI

Mosher K.I., Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer’s disease. Biochem. Pharmacol. 2014;88:594–604. doi: 10.1016/j.bcp.2014.01.008. PubMed DOI PMC

Lucin K.M., O’Brien C.E., Bieri G., Czirr E., Mosher K.I., Abbey R.J., Mastroeni D.F., Rogers J., Spencer B., Masliah E., et al. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer’s disease. Neuron. 2013;79:873–886. doi: 10.1016/j.neuron.2013.06.046. PubMed DOI PMC

Lamkanfi M., Vande Walle L., Kanneganti T.D. Deregulated inflammasome signaling in disease. Immunol. Rev. 2011;243:163–173. doi: 10.1111/j.1600-065X.2011.01042.x. PubMed DOI PMC

Koenigsknecht-Talboo J., Landreth G.E. Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 2005;25:8240–8249. doi: 10.1523/JNEUROSCI.1808-05.2005. PubMed DOI PMC

Heneka M.T., Kummer M.P., Stutz A., Delekate A., Schwartz S., Vieira-Saecker A., Griep A., Axt D., Remus A., Tzeng T., et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493:674–678. doi: 10.1038/nature11729. PubMed DOI PMC

Nagelhus E.A., Amiry-Moghaddam M., Bergersen L.H., Bjaalie J.G., Eriksson J., Gundersen V., Leergaard T.B., Morth J.P., Storm-Mathisen J., Trop R., et al. The glia doctorine: Addressing the role of glial cells in healthy brain ageing. Mech. Ageing Dev. 2013;134:449–459. doi: 10.1016/j.mad.2013.10.001. PubMed DOI

Choi S.S., Lee H.J., Lim I., Satoh J., Kim S.U. Human astrocytes: Secretome profiles of cytokines and chemokines. PLoS ONE. 2014;9:e92325. doi: 10.1371/journal.pone.0092325. PubMed DOI PMC

Sykova E. Glial diffusion barriers during aging and pathological states. Prog. Brain Res. 2001;132:339–363. PubMed

Vargova L., Sykova E. Astrocytes and extracellular matrix in extrasynaptic volume transmission. Philos. Trans. R. Soc. Lond. B. 2014;369 doi: 10.1098/rstb.2013.0608. PubMed DOI PMC

Swanson R.A., Ying W., Kauppinen T.M. Astrocyte influences on ischemic neuronal death. Curr. Mol. Med. 2004;4:193–205. doi: 10.2174/1566524043479185. PubMed DOI

Pekny M., Wilhelmsson U., Bogestal Y.R., Pekna M. The role of astrocytes and complement system in neural plasticity. Int. Rev. Neurobiol. 2007;82:95–111. PubMed

Apelt J., Schliebs R. Β-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res. 2001;894:21–30. doi: 10.1016/S0006-8993(00)03176-0. PubMed DOI

Papadopoulos M.C., Verkman A.S. Aquaporin water channels in the nervous system. Nat. Rev. Neurosci. 2013;14:265–277. doi: 10.1038/nrn3468. PubMed DOI PMC

Butterfield D.A., Pocernich C.B. The glutamatergic system and Alzheimer’s disease: Therapeutic implications. CNS Drugs. 2003;17:641–652. doi: 10.2165/00023210-200317090-00004. PubMed DOI

Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: The role of Aβ1-42. J. Neurochem. 2001;78:413–416. doi: 10.1046/j.1471-4159.2001.00451.x. PubMed DOI

Masliah E., Alford M., de Teresa R., Mallory M., Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann. Neurol. 1996;40:759–766. doi: 10.1002/ana.410400512. PubMed DOI

Korn T., Magnus T., Jung S. Autoantigen specific T cells inhibit glutamate uptake in astrocytes by decreasing expression of astrocytic glutamate transporter GLAST: A mechanism mediated by tumor necrosis factor-α. FASEB J. 2005;19:1878–1880. doi: 10.1096/fj.05-3748fje. PubMed DOI

Zou J., Wang Y.X., Dou F.F., Lu H.Z., Ma Z.W., Lu P.H., Xu X.M. Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem. Int. 2010;56:577–584. doi: 10.1016/j.neuint.2009.12.021. PubMed DOI PMC

Olabarria M., Noristani H.N., Verkhratsky A., Rodriguez J.J. Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer’s disease mouse model: Mechanism of deficient glutamategic transmission? Mol. Neurodegener. 2011;6:55. doi: 10.1186/1750-1326-6-55. PubMed DOI PMC

Kulijewicz-Nawrot M., Verkhratsky A., Chvatal A., Sykova E., Rodriguez J.J. Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer’s disease. J. Anat. 2012;221:252–262. doi: 10.1111/j.1469-7580.2012.01536.x. PubMed DOI PMC

Oberstein T.J., Spitzer P., Klafki H.W., Linning P., Neff F., Knolker H.J., Lewczuk P., Wiltfang J., Kornhuber J., Maler J.M. Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides. Neurobiol. Dis. 2015;73:24–35. doi: 10.1016/j.nbd.2014.08.031. PubMed DOI

Yin K.J., Cirrito J.R., Yan P., Hu X., Xiao Q., Pan X., Bateman R., Song H., Hsu F.F., Turk J., et al. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism. J. Neurosci. 2006;26:10939–10948. doi: 10.1523/JNEUROSCI.2085-06.2006. PubMed DOI PMC

Kanemitsu H., Tomiyama T., Mori H. Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett. 2003;350:113–116. doi: 10.1016/S0304-3940(03)00898-X. PubMed DOI

Eckman E.A., Eckman C.B. Aβ-degrading enzymes: Modulators of Alzheimer’s disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 2005;33:1101–1105. doi: 10.1042/BST20051101. PubMed DOI

Elshourbagy N.A., Liao W.S., Mahley R.W., Taylor J.M. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. USA. 1985;82:203–207. doi: 10.1073/pnas.82.1.203. PubMed DOI PMC

Pitas R.E., Boyles J.K., Lee S.H., Foss D., Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta. 1987;917:148–161. doi: 10.1016/0005-2760(87)90295-5. PubMed DOI

Nakai M., Kawamata T., Taniguchi T., Maeda K., Tanaka C. Expression of apolipoprotein E mRNA in rat microglia. Neurosci. Lett. 1996;211:41–44. doi: 10.1016/0304-3940(96)12716-6. PubMed DOI

Hatters D.M., Peters-Libeu C.A., Weisgraber K.H. Apolipoprotein E structure: Insights into function. Trends Biochem. Sci. 2006;31:445–454. doi: 10.1016/j.tibs.2006.06.008. PubMed DOI

Kanekiyo T., Xu H., Bu G. ApoE and Aβ in Alzheimer’s disease: Accidental encounters or partners? Neuron. 2014;81:740–754. doi: 10.1016/j.neuron.2014.01.045. PubMed DOI PMC

Holtzman D.M., Herz J., Bu G. Apolipoprotein E and apolipoprotein E receptors: Normal biology and role in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2 doi: 10.1101/cshperspect.a006312. PubMed DOI PMC

Basak J.M., Verghese P.B., Yoon H., Kim J., Hotzman D.M. Low-density lipoprotein receptor represent an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. J. Biol. Chem. 2012;287:13959–13971. doi: 10.1074/jbc.M111.288746. PubMed DOI PMC

Myung N.H., Zhu X., Kruman I.I., Castellani R.J., Petersen R.B., Siedlak S.L., Perry G., Smith M.A., Lee H.G. Evidence of DNA damage in Alzheimer disease: Phosphorylation of histone H2AX in astrocytes. Age. 2008;30:209–215. doi: 10.1007/s11357-008-9050-7. PubMed DOI PMC

Bhat R., Crowe E.P., Bitto A., Moh M., Katsetos C.D., Garcia F.U., Johnson F.B., Trojanowski J.Q., Sell C., Torres C. Astrocyte senescence as a component of Alzheimer’s disease. PLoS ONE. 2012;7:e45069. doi: 10.1371/journal.pone.0045069. PubMed DOI PMC

Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., van Eldik L., et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 2006;26:10129–10140. doi: 10.1523/JNEUROSCI.1202-06.2006. PubMed DOI PMC

Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol. Aging. 2003;24:1063–1070. doi: 10.1016/j.neurobiolaging.2003.08.012. PubMed DOI

Rohn T.T., Vyas V., Hernandez-Estrada T., Nichol K.E., Christie L.A., Head E. Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. J. Neurosci. 2008;28:3051–3059. doi: 10.1523/JNEUROSCI.5620-07.2008. PubMed DOI PMC

Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging. 2000;21:383–421. doi: 10.1016/S0197-4580(00)00124-X. PubMed DOI PMC

Montkowski A., Poetting M., Mederer A., Holsboer F. Behavioural performance in three substrains of mouse strain 129. Brain Res. 1997;762:12–18. doi: 10.1016/S0006-8993(97)00370-3. PubMed DOI

Balogh S.A., McDowell C.S., Stavnezer A.J., Denenberg V.H. A behavioral and neuroanatomical assessment of an inbred substrain of 129 mice with behavioral comparisons to C57BL/6J mice. Brain Res. 1999;836:38–48. doi: 10.1016/S0006-8993(99)01586-3. PubMed DOI

Gerlai R. Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype? Trends Neurosci. 1996;19:177–181. doi: 10.1016/S0166-2236(96)20020-7. PubMed DOI

Wolfer D.P., Muller U., Stagliar M., Lipp H.P. Assessing the effects of the 129/Sc genetic background on swimming navigation learning in transgenic mutants: A study using mice with a modified β-amyloid precursor protein gene. Brain Res. 1997;771:1–13. doi: 10.1016/S0006-8993(97)00673-2. PubMed DOI

Takeda T. Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem. Res. 2009;34:639–659. doi: 10.1007/s11064-009-9922-y. PubMed DOI

Ma Q., Qiang J., Gu P., Wang Y., Geng Y., Wang M. Age-related autophagy alterations in the brain of senescence accelerated mouse prone 8 (SAMP8) mice. Exp. Gerontol. 2011;46:533–541. doi: 10.1016/j.exger.2011.02.006. PubMed DOI

Alvarez-Garcia O., Vega-Naredo I., Sierra V., Caballero B., Tomas-Zapico C., Camins A., Garcia J.J., Pallas M., Coto-Montes A. Elevated oxidative stress in the brain of senescence-accelerated mice at 5 months of age. Biogerontology. 2006;7:43–52. doi: 10.1007/s10522-005-6041-2. PubMed DOI

Morley J.E., Farr S.A., Kumar V.B., Armbrecht H.J. The SAMP8 mouse: A model to develop therapeutic interventions for Alzheimer’s disease. Curr. Pharm. Des. 2012;18:1123–1130. doi: 10.2174/138161212799315795. PubMed DOI

Li M., Inaba M., Guo K., Abraham N.G., Ikehara S. Amelioration of cognitive ability in senescence-accelerated mouse prone 8 (SAMP8) by intra-bone marrow-bone marrow transplantation. Neurosci. Lett. 2009;465:36–40. doi: 10.1016/j.neulet.2009.09.001. PubMed DOI

Chouliaras L., Rutten B.P., Kenis G., Peerbooms O., Visser P.J., Verhey F., van Os J., Steinbusch H.W., van den Hove D.L. Epigenetic regulation in the pathophysiology of Alzheimer’s disease. Prog. Neurobiol. 2010;90:498–510. doi: 10.1016/j.pneurobio.2010.01.002. PubMed DOI

Lee H.J., Lee J.K., Lee H., Carter J.E., Chang J.W., Oh W., Yang Y.S., Suh J.G., Lee B.H., Jin H.K., et al. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol. Aging. 2012;33:588–602. doi: 10.1016/j.neurobiolaging.2010.03.024. PubMed DOI

Park H.J., Shin J.Y., Lee B.R., Kim H.O., Lee P.H. Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model. Cell Transpl. 2012;21:1629–1640. doi: 10.3727/096368912X640556. PubMed DOI

Martinez-Morales P.L., Revilla A., Ocana I., Gonzalez C., Sainz P., McGuire D., Liste I. Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev. 2013;9:685–699. doi: 10.1007/s12015-013-9443-6. PubMed DOI

Forostyak S., Homola A., Turnovcova K., Svitil P., Jendelova P., Sykova E. Intrathecal delivery of mesenchymal stromal cells protects the structure of altered perineuronal nets in SOD1 rats and amends the course of ALS. Stem Cells. 2014;32:3163–3172. doi: 10.1002/stem.1812. PubMed DOI PMC

Mazzini L., Vercelli A., Ferrero I., Boido M., Cantello R., Fagioli F. Transplantation of mesenchymal stem cells in ALS. Prog. Brain Res. 2012;201:333–359. PubMed

Hayashi T., Wakao S., Kitada M., Ose T., Watabe H., Kuroda Y., Mitsunaga K., Matsuse D., Shigemoto T., Ito A., et al. Autologous mesenchymal stem cell-derived dopaminergic neurons function in parkinsonian macaques. J. Clin. Investig. 2013;123:272–284. doi: 10.1172/JCI62516. PubMed DOI PMC

Glavaski-Joksimovic A., Bohn M.C. Mesenchymal stem cells and neuroregeneration in Parkinson’s disease. Exp. Neurol. 2013;247:25–38. doi: 10.1016/j.expneurol.2013.03.016. PubMed DOI

Kern S., Eichler H., Stoeve J., Kluter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294–1301. doi: 10.1634/stemcells.2005-0342. PubMed DOI

Kassem M. Abdallah, B.M. Human bone-marrow-derived mesenchymal stem cells: Biological characteristics and potential role in therapy of degenerative diseases. Cell Tissue Res. 2008;331:157–163. doi: 10.1007/s00441-007-0509-0. PubMed DOI

Fukuchi Y., Nakajima H., Sugiyama D., Hirose I., Kitamura T., Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells. 2004;22:649–658. doi: 10.1634/stemcells.22-5-649. PubMed DOI

Wyse R.D., Dunbar G.L., Rossignol J. Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int. J. Mol. Sci. 2014;15:1719–1745. doi: 10.3390/ijms15021719. PubMed DOI PMC

Harting M.T., Jimenez F., Xue H., Fischer U.M., Baumgartner J., Dash P.K., Cox C.S. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J. Neurosurg. 2009;110:1189–1197. doi: 10.3171/2008.9.JNS08158. PubMed DOI PMC

Danielyan L., Schafer R., von Ameln-Mayerhofer A., Buadze M., Geisler J., Klopher T., Burkhardt U., Proksch B., Verleysdonk S., Ayturan M., et al. Intranasal delivery of cells to the brain. Eur. J. Cell Biol. 2009;88:315–324. doi: 10.1016/j.ejcb.2009.02.001. PubMed DOI

Paul C., Samdani A.F., Betz R.R., Fischer I., Neuhuber B. Grafting of human bone marrow stromal cells into spinal cord injury: A comparison of delivery methods. Spine. 2009;34:328–334. doi: 10.1097/BRS.0b013e31819403ce. PubMed DOI PMC

Urdzikova L.M., Ruzicka J., LaBagnara M., Karova K., Kubinova S., Jirakova K., Murali R., Sykova E., Jhanwar-Uniyal M., Jendelova P. Human mesenchymal stem cells modulate inflammatory cytokines after spinal cord injury in rat. Int. J. Mol. Sci. 2014;15:11275–11293. doi: 10.3390/ijms150711275. PubMed DOI PMC

Yun H.M., Kim H.S., Park K.R., Shin J.M., Kang A.R., Lee K., Song S., Kim Y.B., Han S.B., Chung H.M., et al. Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1-42-induced mouse model of Alzheimer’s disease. Cell Death Dis. 2013;4:e958. doi: 10.1038/cddis.2013.490. PubMed DOI PMC

Ikehara S., Li M. Stem cell transplantation improves aging-related disease. Front. Cell Dev. Biol. 2014;2:16. doi: 10.3389/fcell.2014.00016. PubMed DOI PMC

Lee J.K., Jin H.K., Bae J.S. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-β deposition and accelerate the activation of microglia in an acutely induced Alzheimer’s disease mouse model. Neurosci. Lett. 2009;450:136–141. doi: 10.1016/j.neulet.2008.11.059. PubMed DOI

Lee J.K., Jin H.K., Endo S., Schuchman E.H., Carter J.E., Bae J.S. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-β deposition and rescues memory deficits in Alzheimer’s disease mice by modulation of immune responses. Stem Cells. 2010;28:329–343. doi: 10.1002/stem.277. PubMed DOI

Butovsky O., Talpalar A.E., Ben-Yaakov K., Schwartz M. Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-γ and IL-4 render them protective. Mol. Cell. Neurosci. 2005;29:381–393. doi: 10.1016/j.mcn.2005.03.005. PubMed DOI

Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., Schwartz M. Glatiramer acetate fights against Alzheimer’s disease by inducing dendritic-like microglia expression insulin-like growth factor 1. Proc. Natl. Acad. Sci. USA. 2006;103:11784–11789. doi: 10.1073/pnas.0604681103. PubMed DOI PMC

Nemeth K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., Robey P.G., Leelahavanichkul K., Koller B.H., Brown J.M., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009;15:42–49. doi: 10.1038/nm.1905. PubMed DOI PMC

Chen W.W., Blurton-Jones M. Can stem cells be used to treat or model Alzheimer disease? Stem Cells. 2012;30:2612–2618. doi: 10.1002/stem.1240. PubMed DOI PMC

Ma S., Xie N., Li W., Yuan B., Shi Y., Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ. 2014;21:216–225. doi: 10.1038/cdd.2013.158. PubMed DOI PMC

Parr A.M., Kulbatski I., Tator C.H. Transplantation of adult rat spinal cord stem/progenitor cells for spinal cord injury. J. Neurotrauma. 2007;24:835–845. doi: 10.1089/neu.2006.3771. PubMed DOI

Munoz J.R., Stoutenger B.R., Robinson A.P., Spees J.L., Prockop D.J. Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc. Natl. Acad. Sci. USA. 2005;102:18171–18176. doi: 10.1073/pnas.0508945102. PubMed DOI PMC

Kan I., Barhum Y., Melamed E., Offen D. Mesenchymal stem cells stimulate endogenous neurogenesis in the subventricular zone of adult mice. Stem Cell Rev. 2011;7:404–412. doi: 10.1007/s12015-010-9190-x. PubMed DOI

Kim S., Chang K.A., Kim J.A., Park H.G., Ra J.C., Kim H.S., Suh Y.H. The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer’s disease mice. PLoS ONE. 2012;7:e45757. doi: 10.1371/journal.pone.0045757. PubMed DOI PMC

Tfilin M., Sudai E., Merenlender A., Gispan I., Yadid G., Turgeman G. Mesenchymal stem cells increase hippocampal neurogenesis and counteract depressive-like behavior. Mol. Psychiatry. 2010;15:1164–1175. doi: 10.1038/mp.2009.110. PubMed DOI

Lu S., Lu C., Han Q., Li J., Du Z., Liao L., Zhao R.C. Adipose-derived mesenchymal stem cells protect PC12 cells from glutamate excitotoxicity-induced apoptosis by upregulation of XIAP through PI3-K/Akt activation. Toxicology. 2011;279:189–195. doi: 10.1016/j.tox.2010.10.011. PubMed DOI

Lois C., Alvarez-Buylla A. Long-distance neuronal migration in the adult mammalian brain. Science. 1994;264:1145–1148. doi: 10.1126/science.8178174. PubMed DOI

Alvarez-Buylla A., Garcia-Verdugo J.M., Tramontin A.D. A unified hypothesis on the lineage of neural stem cells. Nat. Rev. Neurosci. 2001;2:287–293. doi: 10.1038/35067582. PubMed DOI

Cameron H.A., McKay R.D. Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J. Comp. Neurol. 2001;435:406–417. doi: 10.1002/cne.1040. PubMed DOI

Zhao C., Deng W., Gage F.H. Mechanisms and functional implications of adult neurogenesis. Cell. 2008;132:645–660. doi: 10.1016/j.cell.2008.01.033. PubMed DOI

Ahlenius H., Visan V., Kokaia M., Lindvall O., Kokaia Z. Neural stem and progenitor cells retain their potential for proliferation and differentiation into functional neurons despite lower number in aged brain. J. Neurosci. 2009;29:4408–4419. doi: 10.1523/JNEUROSCI.6003-08.2009. PubMed DOI PMC

Miranda C.J., Braun L., Jiang Y., Hester M.E., Zhang L., Riolo M., Wang H., Rao M., Altura R.A., Kaspar B.K. Aging brain microenvironment decreases hippocampal neurogenesis through Wnt-mediated survivin signaling. Aging Cell. 2012;11:542–552. doi: 10.1111/j.1474-9726.2012.00816.x. PubMed DOI PMC

Lee S.W., Clemenson G.D., Gage F.H. New neurons in an aged brain. Behav. Brain Res. 2012;227:497–507. doi: 10.1016/j.bbr.2011.10.009. PubMed DOI PMC

Ferron S.R., Marques-Torrejon M.A., Mira H., Flores I., Taylor K., Blasco M.A., Farinas I. Telomere shortening in neural stem cells disrupts neuronal differentiation and neuritogenesis. J. Neurosci. 2009;29:14394–14407. doi: 10.1523/JNEUROSCI.3836-09.2009. PubMed DOI PMC

Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N.A., Muller F.J., Loring J.F., Yamasaki T.R., Poon W.W., Green K.N., LaFerla F.M. Neural stem cell improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 2009;106:13594–13599. doi: 10.1073/pnas.0901402106. PubMed DOI PMC

Sugaya K. Possible use of autologous stem cell therapies for Alzheimer’s disease. Curr. Alzheimer Res. 2005;2:367–376. doi: 10.2174/1567205054367919. PubMed DOI

Waldau B., Shetty A.K. Behavior of neural stem cells in the Alzheimer brain. Cell. Mol. Life Sci. 2008;65:2372–2384. doi: 10.1007/s00018-008-8053-y. PubMed DOI PMC

Rivera F.J., Siebzehnrubl F.A., Kandasamy M., Couillard-Despres S., Caioni M., Poehler A.M., Berninger B., Sandner B., Bogdahn U., Goetz M., et al. Mesenchymal stem cells promote oligodendroglial differentiation in hippocampal slice cultures. Cell. Physiol. Biochem. 2009;24:317–324. doi: 10.1159/000233256. PubMed DOI

Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., et al. CD36 ligands promote sterile inflammation through assembly of a toll like receptor 4 and 6 heterodimer. Nat. Immunol. 2010;11:155–161. doi: 10.1038/ni.1836. PubMed DOI PMC

Reed-Geaghan E.G., Savage J.C., Hise A.G., Landreth G.E. CD14 and Toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation. J. Neurosci. 2009;29:11982–11992. doi: 10.1523/JNEUROSCI.3158-09.2009. PubMed DOI PMC

Lim J.E., Kou J., Song M., Pattanayak A., Jin J., Lalonde R., Fukuchi K. MyD88 deficiency ameliorates β-amyloidosis in an animal model of AD. Am. J. Pathol. 2011;179:1095–1103. doi: 10.1016/j.ajpath.2011.05.045. PubMed DOI PMC

Malm T., Koistinaho J., Kanninen K. Utilization of APPswe/PS1dE9 transgenic mice in research of Alzheimer’s disease: Focus on gene therapy and cell-based therapy applications. Int. J. Alzheimers Dis. 2011;2011 doi: 10.4061/2011/517160. PubMed DOI PMC

Fischer W., Wictorin K., Bjorklund A., Williams L.P., Varon S., Gage F.H. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 1987;329:65–68. doi: 10.1038/329065a0. PubMed DOI

Pan W., Banks W.A., Kastin A.J. Permeability of the blood-brain barrier to neurotrophins. Brain Res. 1998;788:87–94. doi: 10.1016/S0006-8993(97)01525-4. PubMed DOI

Williams L.R. Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Exp. Neurol. 1991;113:31–37. doi: 10.1016/0014-4886(91)90143-Z. PubMed DOI

Tuszynski M.H., Thal L., Pay M., Salmon D.P., Sang U H., Bakay R., Patel P., Blesch A., Vahlsing H.L., Ho G., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med. 2005;11:551–555. doi: 10.1038/nm1239. PubMed DOI

Rafii M.S., Baumann T.L., Bakay R.A., Ostrove J.M., Siffert J., Fleisher A.S., Herzog C.D., Barba D., Pay M., Salmon D.P., et al. A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease. Alzheimers Dement. 2014;10:571–581. doi: 10.1016/j.jalz.2013.09.004. PubMed DOI

Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat. Med. 2009;15:331–337. doi: 10.1038/nm.1912. PubMed DOI PMC

Connor B., Young D., Yan Q., Faull R.L., Synek B., Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Mol. Brain Res. 1997;49:71–81. doi: 10.1016/S0169-328X(97)00125-3. PubMed DOI

Blurton-Jones M., Spencer B., Michael S., Castello N.A., Agazaryan A.A., Davis J.L., Muller F.J., Loring J.F., Masliah E., LaFerla F.M. Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res. Ther. 2014;5:46. doi: 10.1186/scrt440. PubMed DOI PMC

Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676. doi: 10.1016/j.cell.2006.07.024. PubMed DOI

Lapasset L., Milhavet O., Prieur A., Besnard E., Babled A., Ait-Hamou N., Leschik J., Pellestor F., Ramirez J.M., de Vos J., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev. 2011;25:2248–2253. doi: 10.1101/gad.173922.111. PubMed DOI PMC

Yagi T., Kosakai A., Ito D., Okada Y., Akamatsu W., Nihei Y., Nabetani A., Ishikawa F., Arai Y., Hirose N., et al. Establishment of induced pluripotent stem cells from centenarians for neurodegenerative disease research. PLoS ONE. 2012;7:e41572. doi: 10.1371/journal.pone.0041572. PubMed DOI PMC

Yagi T., Ito D., Okada Y., Akamatsu W., Nihei Y., Yoshizaki T., Yamanaka S., Okano H., Suzuki N. Modeling familial Alzheimer’s disease with induced pluripotent stem cells. Hum. Mol. Genet. 2011;20:4530–4539. doi: 10.1093/hmg/ddr394. PubMed DOI

Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., van Gorp S., Nazor K.L., Bascolo F.S., et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature. 2012;482:216–220. doi: 10.1038/nature10821. PubMed DOI PMC

Isobe K., Cheng Z., Nishio N., Suganya T., Tanaka Y., Ito S. iPSCs, aging and age-related diseases. N. Biotechnol. 2014;31:411–421. doi: 10.1016/j.nbt.2014.04.004. PubMed DOI

Blasco M.A. Telomere length, stem cells and aging. Nat. Chem. Biol. 2007;3:640–649. doi: 10.1038/nchembio.2007.38. PubMed DOI

Marion R.M., Strati K., Li H., Tejera A., Schoeftner S., Ortega S., Serrano M., Blasco M.A. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell. 2009;4:141–154. doi: 10.1016/j.stem.2008.12.010. PubMed DOI

Huang J., Wang F., Okuka M., Liu N., Ji G., Ye X., Zuo B., Li M., Liang P., Ge W.W., et al. Association of telomere length with authentic pluripotency of ES/iPS cells. Cell Res. 2011;21:779–792. doi: 10.1038/cr.2011.16. PubMed DOI PMC

Golde T.E., Miller V.M. Proteinopathy-induced neuronal senescence: A hypothesis for brain failure in Alzheimer’s and other neurodegenerative diseases. Alzheimers Res. Ther. 2009;1:5. doi: 10.1186/alzrt5. PubMed DOI PMC

Hunter S., Arendt T., Brayne C. The senescence hypothesis of disease progression in Alzheimer’s disease: An integrated matrix of disease pathways for FAD and SAD. Mol. Neurobiol. 2013;48:556–570. doi: 10.1007/s12035-013-8445-3. PubMed DOI

Amemori T., Ermakova I.V., Buresova O., Zigova T., Racekova E., Bures J. Brain transplants enhance rather than reduce the impairment of spatial memory and olfaction in bulbectomized rats. Behav. Neurosci. 1989;103:61–70. doi: 10.1037/0735-7044.103.1.61. PubMed DOI

Vorhees C.V., Williams M.T. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006;1:848–858. doi: 10.1038/nprot.2006.116. PubMed DOI PMC